<DOC>
	<DOC>NCT01999673</DOC>
	<brief_summary>The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.</brief_summary>
	<brief_title>Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key Male or female at least 18 years of age Histologically or cytologically confirmed and documented stage IIIb/IV nonsquamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition) Radiographic disease recurrence or progression during or after frontline platinumbased doublet chemotherapy. For patients with known epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations, appropriate targeted treatment should have been used. Mutation testing is not required. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate hematologic, renal and hepatic function Squamous, small cell, carcinoid, adenosquamous, largecell neuroendocrine, or mixed histology containing smallcell or squamouscell NSCLC Known history of bleeding disorders, eg, von Willebrand disease or hemophilia Cavitary tumors or tumors invading or abutting large blood vessels Clinically significant bleeding such as gross hematuria, GI bleeding, and hemoptysis within the 6 months before screening Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening Grade 2 or higher peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SUNRISE</keyword>
	<keyword>PPHM 1202</keyword>
	<keyword>Bavituximab</keyword>
	<keyword>Peregrine</keyword>
</DOC>